Procaine Benzylpenicillin
drug drugOn this page
Also known as BicillinCilicaine syringeDepocillinE707
Summary
Procaine Benzylpenicillin (CHEMBL1628385) is an approved small molecule (ATC J01CE09); indicated across 1 condition including bacterial infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01CE09
- Indications: 1 condition
- Chemistry: 570.7 Da · C29H38N4O6S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1628385 |
| Name | Procaine Benzylpenicillin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5903 |
| ChEBI | CHEBI:52154 |
| ATC | J01CE09 |
| Molecular formula | C29H38N4O6S |
| Molecular weight | 570.7 |
| InChIKey | WHRVRSCEWKLAHX-LQDWTQKMSA-N |
SMILES: CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
IUPAC name: 2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Also known as: Bicillin, Cilicaine syringe, Depocillin, E707, Procaine benzylpenicillin, PROCAINE BENZYLPENICILLIN
Parent form; salt/anhydrous children: CHEMBL1200936
Patent coverage: 1,606 distinct patent families (4,730 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,088 (65%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.